Effect of dapagliflozin on the prognosis of patients with acute myocardial infarction undergoing percutaneous coronary intervention

Table 2 Adverse cardiovascular events according to the DAPA administration during follow-up

Adverse Cardiovascular events	DAPA-free	DAPA	P value
Adverse Cardiovascular events	n = 645	n = 141	P value
MACE, n (%)	118 (18.3)	12 (8.5)	0.018
Overall death, n (%)	9 (1.4)	1 (0.7)	0.440
Heart failure, n (%)	67 (10.4)	3 (2.1)	< 0.001
Non-fatal MI, n (%)	76 (11.8)	5 (3.5)	0.001
Non-fatal stroke, n (%)	15 (2.3)	0 (0)	0.050
URR, n (%)	98 (15.2)	11 (7.8)	0.012

The MACE was defined as the composite of overall death, HF, non-fatal MI, non-fatal stroke, and URR
MACE major adverse cardiovascular events; MI myocardial infarction; URR unplanned repeat revascularization

ISSN: 1475-2840